伊立替康联合卡培他滨治疗转移性结直肠癌疗效观察

Clinical observation on irinotecan and capecitabine in the treatment of advanced or mestastatic colorectal cancer

目的:探讨伊立替康(CPT-11)联合卡培他滨(capecitabine,Cap)治疗复发转移性结直肠癌的疗效与毒性。方法:26例进展期结直肠癌患者接受卡培他滨口服2000mg/(m2.d),分2次,连服14d;CPT-1160mg/m2,静脉滴入,90min,d1、d8,每3周重复。结果:26例患者用药后均可评价疗效,共完成化疗136个周期,无完全缓解病例,PR8例(29%),SD12例(45%),PD6例(26%),中位疾病进展时间7.2个月,疾病控制率74%;远期疗效:平均疾病缓解时间7.2个月,中位生存时间14.7个月。常见的毒副反应为白细胞降低,胃肠道反应主要为腹泻,手足综合征1例。结论:CPT-11联合卡培他滨治疗晚期转移性结直肠癌疗效好且不良反应可耐受。

OBJECTIVE： To evaluate the efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with metastatic colorectal adenocarcinoma. METHODS： Twenty-six patients with histologically proven advanced colorectal adenocarcinoma received a scond-line chemotherapy with irinotecan 60 mg/m^2 on day 1,8 and capecitabine 2 000 mg（m^2·d） as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest. Treatment was repeated every 3 weeks. RESULTS： Twenty-six patients were registered, and all were assessable for responses. PR was 8（29%）, SD was 12（45%）, andPDwas 6（26%）. The median time to progression was 7.2 months and the median survival time was 14.7 months. In 26 cases with 136 cycles of chemotherapy, frequently encountered therapy-related events were leukopenia and gastrointestinal side effects including diarrhea. Severe hand-and-foot syndrome was observed in only 1 patient. CONCLUSION： The combination chemotherapy of irinotecan and capecitabine is an active and tolerable regimen for advanced colorectal adenocarcinoma.